Brief: Almirall To Start Phase III Study On Lebrikizumab For Nummular Eczema

Almirall

15/01/2026 07:07

Jan 15 (Reuters) - Almirall SA ALM.MC:

ANNOUNCES “LUMINE”, PHASE III CLINICAL STUDY ASSESSING EFFICACY OF LEBRIKIZUMAB FOR TREATMENT OF NUMMULAR ECZEMA

PHASE III STUDY TO START IN 2026

PRIMARY ENDPOINT IS IMPROVEMENT OF IGA-NE

Source text

Further company coverage: ALM.MC

(Gdansk Newsroom)

((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))